A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Latest Information Update: 27 Apr 2022
At a glance
- Drugs Arbaclofen (Primary)
- Indications Multiple sclerosis; Muscle spasticity
- Focus Adverse reactions; Registrational
- Sponsors Osmotica Pharmaceutical; RVL Pharmaceuticals
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 14 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.